CommercialAdministrativeMedium impact
07.07.03n, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])
Independence Blue Cross·Dermatology, Oncology·Pharmacy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
IBX Commercial updated their photodynamic therapy (PDT) policy for treatments using Levulan Kerastick or Ameluz. This appears to be a medical coding, guidelines, or informational update that may affect billing procedures for PDT treatments.
Action Required
By October 20, 2025: Billing team should review the updated PDT policy at the IBX website to understand any changes to coding guidelines, coverage criteria, or documentation requirements for photodynamic therapy using Levulan Kerastick or Ameluz. Update billing procedures and staff training as needed based on the full policy content.